Brought to you by 
Lilly licenses PDL's antibody technology
14 Nov 2000
Executive Summary
In exchange for (uf)$1.7mm in up-front signing fees, annual maintenance fees, milestones, and royalties, Eli Lilly will license Protein Design Labs' antibody technology to humanize one of its own murine monoclonal antibodies.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly licenses PDL's antibody technology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice